An Expert View from Mark Samuels, chief executive, British Biosimilars Association.
Biosimilars are among the UK National Health Service's (NHS) most crucial medicines. They are essential for supporting patient access to treatments while helping the NHS to remain affordable, yet biosimilars’ future is under threat in the UK.
The progress in biosimilar adoption in this country is a story built on collaboration, and in a few short years, the UK went from lagging to leading in terms of take-up compared to other parts of Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze